Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common...

By leading Viracta Therapeutics Inc. ’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal. Wicklow...

On the heels of cancer immunotherapy's clinical success, NK cells - a long-known but underappreciated component of the innate immune system - are emerging as the hottest new tool to fight cancer, with the potential...

NantCell Inc. (Culver City, Calif.) raised $100 million in an equity financing from a single, undisclosed investor, according to an SEC filing. NantCell, which did not respond to inquiries, is one of several subsidiaries of...

Patrick Soon-Shiong is building what he hopes will be a suite of companies under the NantWorks LLC umbrella that together will help revolutionize cancer treatment. The latest is cancer immunotherapy company NantKwest Inc. (NASDAQ:NK), which...

NantCell Inc. raised $75 million in an equity financing from a single investor, according to an SEC filing. NantCell, which did not respond to inquiries, is one of several subsidiaries of Patrick Soon-Shiong's NantWorks LLC...